Drug · CHEMBL684
DIETHYLCARBAMAZINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DIETHYLCARBAMAZINE. Drugs and targets, record CHEMBL684. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL684
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases12
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 12Source Open Targets
See all 12 diseasesTrials20
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04410406 | Moxidectin for LF, Cote d'Ivoire (DOLF) | Phase 3 | 164 | 2026-01-29 | diethylcarbamazine | Its name | ClinicalTrials.gov |
| NCT01593722 | Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis | Phase 4 | 155 | 2016-11-09 | diethylcarbamazine | Its name | ClinicalTrials.gov |
| NCT04188301 | Safety and Efficacy of IDA for Onchocerciasis | Phase 2 | 154 | 2023-05-10 | diethylcarbamazine | Its name | ClinicalTrials.gov |
| NCT00511004 | Effect of Albendazole Dose on Treatment of Lymphatic Filariasis | Phase 2 | 40 | 2015-08-31 | diethylcarbamazine | Its name | ClinicalTrials.gov |
| NCT01111305 | Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis | Phase 2 | 31 | 2017-06-01 | diethylcarbamazine | Its name | ClinicalTrials.gov |
| NCT01905423 | Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis | 17,108 | 2017-10-16 | diethylcarbamazine | Its name | ClinicalTrials.gov | |
| NCT02899936 | Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis | 23,789 | diethylcarbamazine | Its name | ClinicalTrials.gov | ||
| NCT03676140 | Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) | Phase 3 | 20,000 | diethylcarbamazine | Its name | ClinicalTrials.gov | |
| NCT07159373 | Better Options for Lymphatic Filariasis Treatment | Phase 3 | 5,100 | diethylcarbamazine | Its name | ClinicalTrials.gov | |
| NCT03177993 | Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji | 4,773 | diethylcarbamazine | Its name | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Diethylcarbamazine vs Ivermectin: Proportion of Subjects Who Clear Microfilaremia | 3 of 6 | 0 of 6 | 12 | NCT01593722 | Trial comparisons |
| Diethylcarbamazine vs Ivermectin: Treatment Efficacy | 0 of 6 | 1 of 6 | 12 | NCT01593722 | Trial comparisons |
| Diethylcarbamazine vs Ivermectin: serious adverse events | 0 of 6 | 0 of 6 | 12 | NCT01593722 | Trial comparisons |
| Reslizumab + DEC vs Placebo + DEC: deaths from any cause | 0 of 4 | 0 of 4 | 8 | NCT01111305 | Trial comparisons |
| Reslizumab + DEC vs Placebo + DEC: serious adverse events | 0 of 4 | 0 of 4 | 8 | NCT01111305 | Trial comparisons |
Papers from its trials25
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 42848323 | DERIVED | 3 | PubMed |
| 40345209 | DERIVED | 1 | PubMed |
| 38587077 | DERIVED | 1 | PubMed |
| 37721964 | DERIVED | 1 | PubMed |
| 37616301 | DERIVED | 1 | PubMed |
| 37262040 | DERIVED | 2 | PubMed |
| 37243712 | DERIVED | 1 | PubMed |
| 37205721 | DERIVED | 1 | PubMed |
| 35533701 | DERIVED | 2 | PubMed |
| 35139070 | DERIVED | 1 | PubMed |
1 to 10 of 25
See all 25 papers from its trialsTests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL684
GET https://conductscience.org/api/drugs/v1/CHEMBL684/papers?page=2